为了更好地了解纽约食管鳞状细胞癌 1 (NY-ESO-1) 和人类白细胞抗原 (HLA) 亚型在治疗决策中的重要性，进一步研究它们在转移性滑膜肉瘤 (mSS) 患者中的患病率和预后影响这是一项针对成人 mSS 的回顾性临床生物学队列研究。患者数据收集自法国肉瘤组织 NetSARC 数据库，并辅以电子病历。收集原发性肿瘤样本，并通过免疫组织化学 (IHC) 分析 NY-ESO-1 表达，并通过 RNA 测序 (RNA-seq) 分析 HLA-A*02 状态。主要队列包括具有可用原发肿瘤样本的患者；通过纳入具有原发性或转移性样本的患者（称为探索性队列）来探讨更大样本量的影响。提供 P 值用于描述目的。在 92 名原发性肿瘤样本患者中，约 25% (n = 23) NY-ESO-1 和 HLA-A*02 表达呈阳性（双阳性）。在 106 名有 IHC 数据的患者中，61% (n = 65) 为 NY-ESO-1 阳性，在 94 名有 RNA-seq 数据的患者中，45% (n = 42) 为 HLA-A*02 阳性。 NY-ESO-1 状态阳性与阴性的中位总生存期 (OS) 分别为 35.3 个月和 21.7 个月（未经调整 P = 0.0428）。我们观察到 HLA-A*02 阳性患者与 HLA-A*02 阴性患者以及双阳性患者与其他患者的中位 OS 没有差异（均未调整 P > 0.05）。 OS 的多变量分析显示 NY-ESO-1 在原发性肿瘤样本和探索性队列中没有预后影响。然而，在后者中，我们在一线治疗中观察到 NY-ESO-1 表达与 OS 之间存在关联 (P = 0.0041)，但在二线治疗中则没有。原发性肿瘤队列显示 NY-ESO-1 表达与 OS 之间没有关联。 1 表达和 OS（包括按 HLA-A*02 亚型和治疗系分层），在调整重要的预后因素时，可能是由于样本量较小。版权所有 © 2024 作者。由爱思唯尔有限公司出版。保留所有权利。

To better understand the importance of New York esophageal squamous cell carcinoma 1 (NY-ESO-1) and human leukocyte antigen (HLA) subtype in treatment decision making, further investigation of their prevalence and prognostic impact among patients with metastatic synovial sarcoma (mSS) is needed.This was a retrospective clinico-biological cohort study of adults with mSS. Patient data were collected from the French Sarcoma Group NetSARC database and supplemented by electronic medical records. Primary tumor samples were collected and analyzed for NY-ESO-1 expression by immunohistochemistry (IHC) and HLA-A∗02 status by RNA sequencing (RNA-seq). The primary cohort included patients with available primary tumor samples; the impact of a larger sample size was explored by including patients who had either a primary or metastatic sample (termed the exploratory cohort). P values are provided for descriptive purposes.In 92 patients with primary tumor samples, ∼25% (n = 23) were positive for NY-ESO-1 and HLA-A∗02 expression (dual positive). Among 106 patients with IHC data, 61% (n = 65) were NY-ESO-1 positive, and among 94 patients with RNA-seq data, 45% (n = 42) were HLA-A∗02 positive. The median overall survival (OS) for positive versus negative NY-ESO-1 status was 35.3 and 21.7 months, respectively (unadjusted P = 0.0428). We observed no difference in median OS for HLA-A∗02-positive versus -negative and dual-positive patients versus others (both unadjusted P > 0.05). Multivariate analyses of OS showed no prognostic impact for NY-ESO-1 among primary tumor samples and in the exploratory cohort. However, in the latter, we observed an association between NY-ESO-1 expression and OS in the first-line (P = 0.0041) but not in the second-line setting.The primary tumor cohort showed no association between NY-ESO-1 expression and OS (including stratification by HLA-A∗02 subtype and treatment line), when adjusting for important prognostic factors, possibly due to small sample sizes.Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.